These subtypes can be associated with specific biomarkers that are either drug-specific targets or predictors of drug response (e.g., DLL3 in SCLC-A, AURKA in SCLC-N, CDK4/6 in SCLC-Y and IGF1R in SCLC-P). This evidence concerns the gene CDK4 and small cell lung carcinoma.